EP1615631A2 - Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen - Google Patents

Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen

Info

Publication number
EP1615631A2
EP1615631A2 EP03785594A EP03785594A EP1615631A2 EP 1615631 A2 EP1615631 A2 EP 1615631A2 EP 03785594 A EP03785594 A EP 03785594A EP 03785594 A EP03785594 A EP 03785594A EP 1615631 A2 EP1615631 A2 EP 1615631A2
Authority
EP
European Patent Office
Prior art keywords
dopa
derivatives
physiologically tolerable
tolerable salts
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03785594A
Other languages
German (de)
English (en)
French (fr)
Inventor
Rudolf-Giesbert Alken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BDD Berolina Drug Development GmbH
Original Assignee
BDD Berolina Drug Development GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BDD Berolina Drug Development GmbH filed Critical BDD Berolina Drug Development GmbH
Publication of EP1615631A2 publication Critical patent/EP1615631A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • L-DOPA L-DOPA
  • its derivatives and medicaments containing these compounds for the prophylaxis of psychotic diseases
  • the invention relates to the use of 3, 4-dihydroxy-L-phenylalanine (L-DOPA) and its derivatives for the manufacture of medicaments and their use for the prophylaxis of psychotic diseases and for the treatment of diseases caused by disturbed tyrosine transport or tyrosine decarboxylase become.
  • L-DOPA 3, 4-dihydroxy-L-phenylalanine
  • the treatment of symptoms of schizophrenic diseases is currently usually carried out using neuroleptics such as chlorpromazine, haloperidol, sulpiride and their chemical relatives.
  • neuroleptics such as chlorpromazine, haloperidol, sulpiride and their chemical relatives.
  • the suspension of the treatment usually leads to a relapse of the patient.
  • L-DOPA acts on the level of dopamine in the nerve cells of the brain. Unlike dopamine itself, it can cross the blood-brain barrier and is converted to dopamine in the brain.
  • L-DOPA is usually administered in drugs with active additives.
  • combinations of L-DOPA with peripheral decarboxylase inhibitors with inhibitors of catechol-O-methyltransferase (COMT), with inhibitors of monoamine oxidase (MAO) and inhibitors for dopamine- ⁇ -hydroxylase are used.
  • CCT catechol-O-methyltransferase
  • MAO monoamine oxidase
  • Decarboxylase inhibitors used in this connection are, for example, D, L-serine-2- (2, 3, 4-trihydroxybenzyl) hydrazide (benserazide), (-) - La-hydrazino-3, 4-dihydroxy-a-methylhydrocinnamic acid (carbide-opa ), L-serine-2- (2, 3, 4-trihydroxybenzyl) hydrazide, glycine-2- (2, 3, 4-trihydroxybenzyl) hydrazide and L-tyrosine-2- (2, 3, 4-trihydroxybenzyl) hydrazide ,
  • Examples of combination preparations made from L-DOPA and decarboxylase inhibitors include Madopar® (L-DOPA and benserazide
  • COMT inhibitors examples include entacapone (Comtan®) and cabergoline and frequently used MAO inhibitors are selegiline hydrochloride, moclobemide and tranylcypromine.
  • Calcium 5-butylpicolinate and calcium 5-pentylpicolinate are described as inhibitors for dopamine- ⁇ -hydroxylase (DE-A 2 049 115).
  • use for relapse prophylaxis in psychotic diseases, in particular in schizophrenic diseases is preferred.
  • L-DOPA can be used for the prophylaxis of psychotic diseases. This is all the more astonishing since psychotic disorders are known as side effects with high doses of L-DOPA.
  • L-DOPA L-DOPA
  • its derivatives and their physiologically tolerable salts in combination with an enzyme inhibitor or several enzyme inhibitors for the prophylaxis of psychotic diseases and for the treatment of diseases caused by disturbed tyro- sintransport or disturbed tyrosine decarboxylase.
  • the enzyme inhibitor or the enzyme inhibitors are decarboxylase inhibitors and / or catechol-O-methyltransferase inhibitors and / or monoa inoxidase inhibitors and / or ⁇ -hydroxylase inhibitors.
  • the decarboxylase inhibitor is selected from the group consisting of D, L-serine-2- (2, 3,4-trihydroxybenzyl) hydrazide (benserazide), (-) -La-hydrazino-3 , 4-dihydroxy-a-methylhydrocinnamic acid (carbidopa), L-serine-2- (2,3, 4-trihydroxybenzyl) ydrazide, glycine-2- (2, 3, 4-trihydroxybenzyl) hydrazide and L-tyrosine-2- (2, 3, 4-trihydroxybenzyl) hydrazide and their physiologically tolerable salts.
  • catechol-O-methyltransferase inhibitor is selected from entacon and cabergoline and their physiologically tolerable salts.
  • the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobemide and tranylcypromine and their physiologically tolerable salts.
  • the ⁇ -hydroxylase inhibitor is selected from calcium 5-butylpicolinate and calcium 5-pentylpicolinate and their physiologically tolerable salts.
  • Another object of the invention is the use of L-DOPA, its derivatives and their physiologically questionable salts for the production of medicaments for the prophylaxis of psychotic diseases and for the treatment of treatment of diseases caused by impaired tyrosine transport or tyrosine decarboxylase.
  • Another object of the present invention is a pharmaceutical composition which L-DOPA, its derivatives and their physiologically tolerable salts for the prophylaxis of psychotic diseases and for the treatment of diseases which are caused by disturbed tyrosine transport or disturbed tyrosine decarboxylase, in addition to pharmaceutically acceptable auxiliaries and additives , contains.
  • a pharmaceutical composition which contains L-DOPA, its derivatives and their physiologically compatible salts for the prophylaxis of psychotic diseases and for the treatment of diseases which are caused by disturbed tyrosine transport or tyrosine decarboxylase and one or more enzyme inhibitors, in addition to pharmaceutically acceptable auxiliary substances, is particularly advantageous. and additives.
  • composition in which the enzyme inhibitor or the enzyme inhibitors are decarboxylase inhibitors and / or catechol-O-
  • Methyltransferase inhibitors and / or monoamine oxidase inhibitors and / or b-hydroxylase inhibitors are included in Methyltransferase inhibitors and / or monoamine oxidase inhibitors and / or b-hydroxylase inhibitors.
  • the decarboxylase inhibitor is selected from the group consisting of D, L-serine-2- (2,3,4-trihydroxybenzyl) hydrazide (benserazide), (-) - La-hydrazino- 3, -dihydroxy-a-methylhydrocinnamic acid (carbide-opa), L-serine-2- (2, 3, 4-trihydroxybenzyl) hydrazide, glycine-2- (2, 3, -trihydroxybenzyl) hydrazide and L-tyrosine-2 - (2, 3, 4-trihydroxybenzyl) hydrazide and their physiologically tolerable salts.
  • the decarboxylase inhibitor is selected from the group consisting of D, L-serine-2- (2,3,4-trihydroxybenzyl) hydrazide (benserazide), (-) - La-hydrazino- 3, -dihydroxy-a-methylhydrocinnamic acid (carbide-opa), L-
  • Inhibitors are selected from entacapone and cabergoline and their physiologically tolerable salts.
  • composition in which the monoamine oxidase inhibitor is selected from the group consisting of selegiline, moclobe id and tranylcypromine and their physiologically tolerable salts.
  • ⁇ -hydroxylase inhibitor is selected from calcium 5-butyl picolinate and calcium 5-pentyl picolinate and their physiologically tolerable salts.
  • physiologically compatible inorganic and organic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipic acid and Benzoic acid.
  • Other acids that can be used are described, for example, in Progress in Pharmaceutical Research, vol. 10, pages 224-225, Birkhäuser Verlag, Basel and Stuttgart (1966) and Journal of Pharmaceutical Sciences, vol. 66, pages 1-5 (1977).
  • the acid addition salts of L-DOPA and its derivatives are generally in a manner known per se by mixing the free base or its solutions with the corresponding acid or their solutions in an organic solvent, for example a lower alcohol such as methanol, ethanol, etc. -Propanol or isopropanol or a lower ketone such as acetone, methyl ethyl ketone or methyl isobutyl ketone or an ether such as diethyl ether, tetrahydrofuran or dioxane. Mixtures of the solvents mentioned can also be used for better crystal deposition.
  • physiologically compatible aqueous solutions of acid addition salts of the compounds used according to the invention can be prepared in an aqueous acid solution.
  • the acid addition salts of L-DOPA and its derivatives can be used in a manner known per se, e.g. B. with alkalis or ion exchangers, are converted into the free base. Additional salts can be obtained from the free base by reaction with inorganic or organic acids, in particular those which are suitable for forming therapeutically usable salts. These or other salts of the new compound, such as. B. the picrate, can also be used to purify the free base by converting the free base into a salt, separating it and releasing the base from the salt.
  • the present invention also relates to medicaments for oral, buccal, sublingual, nasal, rectal, subeutan, intravenous or intramuscular application and for inhalation, which, in addition to conventional carriers and diluents, contain L-DOPA, a derivative or the acid addition salt thereof as an active ingredient.
  • the medicaments of the invention are produced in a known manner with the customary solid or liquid carriers or diluents and the commonly used pharmaceutical technical adjuvants in accordance with the desired type of application with a suitable dosage.
  • the preferred preparations are in a dosage form which is suitable for oral administration. Dosage forms of this type are, for example, tablets, lozenges, film-coated tablets, coated tablets, capsules, pills, powders, solutions, aerosols or suspensions or depot forms.
  • parenteral preparations such as injection solutions are also suitable. Suppositories may also be mentioned as preparations.
  • Corresponding tablets can be mixed, for example, by mixing the active ingredient with known auxiliaries, for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc and / or agents Achieving a depot effect such as carboxyl polymethylene, carboxylmethyl cellulose, cellulose acetate phthalate or polyvinyl acetate can be obtained.
  • auxiliaries for example inert diluents such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants such as corn starch or alginic acid, binders such as starch or gelatin, lubricants such as magnesium stearate or talc and / or agents Achieving a depot effect such
  • Coated tablets also for controlled or delayed release preparation forms, can accordingly be produced by coating cores produced analogously to the tablets with agents commonly used in tablet coatings, for example polyvinylpyrrolidone or shellac, gum arabic, talc, titanium dioxide or sugar.
  • the coated tablet can also consist of several layers exist, wherein the excipients mentioned above for the tablets can be used.
  • Solutions or suspensions with the active ingredient used according to the invention can additionally taste-improving agents such as saccharin, cyclamate or sugar and z.
  • B. contain flavorings such as vanillin or orange extract. They can also contain suspending agents such as sodium carboxymethyl cellulose or preservatives such as p-hydroxybenzoates.
  • Capsules containing active ingredients can be produced, for example, by mixing the active ingredient with an inert carrier such as milk sugar or sorbitol and encapsulating it in gelatin capsules.
  • Suitable suppositories can be produced, for example, by mixing them with carriers such as neutral fats or polyethylene glycol or their derivatives.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03785594A 2002-12-19 2003-12-18 Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen Withdrawn EP1615631A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10261808A DE10261808A1 (de) 2002-12-19 2002-12-19 Verwendung von L-DOPA, seiner Derivate und diese Verbindungen enthaltender Arzneimittel zur Prophylaxe psychotischer Erkrankungen
PCT/DE2003/004204 WO2004056306A2 (de) 2002-12-19 2003-12-18 Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen

Publications (1)

Publication Number Publication Date
EP1615631A2 true EP1615631A2 (de) 2006-01-18

Family

ID=32478131

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03785594A Withdrawn EP1615631A2 (de) 2002-12-19 2003-12-18 Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen

Country Status (10)

Country Link
EP (1) EP1615631A2 (es)
JP (1) JP2006511558A (es)
CN (1) CN1756542A (es)
AU (1) AU2003294664A1 (es)
CA (1) CA2513077A1 (es)
DE (1) DE10261808A1 (es)
EA (1) EA200500957A1 (es)
MX (1) MXPA05006409A (es)
PL (1) PL377524A1 (es)
WO (1) WO2004056306A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
PL1991522T3 (pl) * 2006-02-17 2017-07-31 Ratiopharm Gmbh Deuterowane pochodne katecholaminy i leki zawierające te związki
CN105078952A (zh) * 2015-08-10 2015-11-25 中国康复研究中心 一种左旋多巴制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52102431A (en) * 1976-02-25 1977-08-27 Kyowa Hakko Kogyo Co Ltd Remedies for mental disorder
IE47082B1 (en) * 1977-07-01 1983-12-14 Merrell Toraude & Co -acetylenic amino acids
US5149786A (en) * 1989-10-12 1992-09-22 Chiron Corporation Dopamine releasing protein and antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004056306A3 *

Also Published As

Publication number Publication date
JP2006511558A (ja) 2006-04-06
EA200500957A1 (ru) 2006-02-24
CA2513077A1 (en) 2004-07-08
WO2004056306A3 (de) 2004-11-11
CN1756542A (zh) 2006-04-05
PL377524A1 (pl) 2006-02-06
WO2004056306A2 (de) 2004-07-08
DE10261808A1 (de) 2004-07-08
MXPA05006409A (es) 2006-05-31
AU2003294664A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
EP1248606B1 (de) Verwendung von fumarsäurederivaten zur behandlung mitochondrialer krankheiten
EP1907386B1 (de) Aminosäuresalze von rosiglitazon
EP1305300A1 (de) Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE2817358A1 (de) Neue therapeutische anwendung von acylderivaten des d,l-carnitin
WO2002102743A9 (de) Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
EP1613571B1 (de) Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel
DE102005014080B4 (de) Additionssalze des Tolperison, Verfahren zu deren Herstellung, Verwendung derselben und diese enthaltende Arzneimittel
EP0132811A1 (de) In 1-Stellung substituierte 4-Hydroxymethyl-pyrrolidinone, Verfahren zu ihrer Herstellung, pharmazeutische Zusammensetzungen und Zwischenprodukte
EP1615631A2 (de) Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen
DE2460929C2 (es)
DE2405094A1 (de) 2-aminoindan-abkoemmlinge, deren herstellung und verwendung
EP0471388B1 (de) Mittel zur Behandlung der Herzinsuffizienz
EP0951907A1 (de) Verwendung von Moxonidin alsThermogenese stimulierend wirksame Arzneimittel
EP0147707A2 (de) 1,7-Diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur Verwendung bei der Bekämpfung von Krankheiten
DE10312809A1 (de) Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern
EP0489043B1 (de) Verwendung des (+)-enantiomeren von anipamil
DE2207460C2 (de) Verwendung von Hydroxycylohexylaminderivaten bei der Behandlung von ödematös atelektatischen Lungenveränderungen
EP0669826A1 (de) (-)-metrifonat enthaltendes arzneimittel
EP0005732A1 (de) Verwendung von 2-Amino-oxazolo- oder 2-Amino-thiazolo-[5,4-d]azepinen sowie deren Säureadditionssalzen zur Herstellung eines Arzneimittels für die Verwendung bei der Bekämpfung von Angina Pectoris
US20070082953A1 (en) Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases
AT396427B (de) Pharmazeutische verwendung eines oxipurinolsalzes
EP0025069B1 (de) Neues Pentylspartein-Salz, dieses enthaltendes Arzneimittel und Verfahren zur Herstellung eines solchen Arzneimittels
EP0109622A1 (de) 7-Phenyl-7-phenoxymethyl-hexahydro-1,4-oxazepine, ihre Herstellung und Verwendung
DE2336560B1 (de) Arzneimittel, enthaltend 1-(2-hydroxy2-indanyl)-propylamin
DE1793799C2 (de) 1 -Phenoxy^-hydroxyO-alkylaminopropane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20051113

Extension state: LV

Payment date: 20051113

17Q First examination report despatched

Effective date: 20060621

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/195 20060101ALI20060609BHEP

Ipc: A61K 31/435 20060101ALI20060609BHEP

Ipc: A61K 31/137 20060101ALI20060609BHEP

Ipc: A61K 31/175 20060101ALI20060609BHEP

Ipc: A61K 31/135 20060101ALI20060609BHEP

Ipc: A61P 25/18 20060101ALI20060609BHEP

Ipc: A61K 31/198 20060101AFI20050713BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DER ERFINDER HAT AUF SEINE NENNUNG VERZICHTET.

17Q First examination report despatched

Effective date: 20060621

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070425